Navigation Links
More than a third of high-risk leukemia patients respond to an experimental new drug

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely cleared from the bone marrow, and as a result, many of these patients were able to undergo potentially curative bone marrow transplants, according to investigators at the Johns Hopkins Kimmel Cancer Center and nine other academic medical centers around the world. Many of the participants who did well with the new drug, quizartinib or AC220, had failed to respond to prior therapies.

"We can put two-thirds to three-quarters of adults with AML into remission with chemotherapy, but there's a 50 percent chance of the disease coming back, which usually ends up being fatal," says Mark Levis, M.D., Ph.D., lead investigator on the study and associate professor of oncology and medicine at Johns Hopkins. "Many patients in this trial were able to go on to receive a potentially life-saving bone marrow transplant. It caught us by surprise how well it works," he adds.

A report on the study is expected to be presented December 9 during a press briefing at the American Society of Hematology's annual meeting in Atlanta.

For the clinical trial, researchers enrolled 137 AML patients, the majority of whom carried a mutation in a gene called FLT3-ITD within their leukemia cells. The FLT3 gene produces an enzyme that signals bone marrow stem cells to divide and replenish. In about a quarter of patients with AML, the disease mutates FLT3 so that the enzyme stays on permanently, causing rapid growth of leukemia cells and making the condition harder to treat.

"A FLT3-ITD mutation tells us that, typically, patients will need very intensive chemotherapy just to achieve a remission, and then the disease will regrow quickly," Levis says. "So, we have learned to try to perform a bone marrow transplant soon after we get the patient into remission, before the cancer relapses." Quizartinib, which blocks the FLT3 enzyme, and is available in liquid oral form, is so potent that it typically starts working in just two days, Levis says, though it may take up to 60 days to completely eliminate AML cells from the bone marrow.

At Johns Hopkins and nine other centers, the 137 AML recruited patients received quizartinib at a starting dose of 90 mg/day for women and 135 mg/day for men, and were treated continuously during 28-day cycles. Study participants either had relapsed, did not respond to second-line chemotherapy or had relapsed following hematopoietic stem cell transplantation.

Forty-four percent (44) of the 99 participants with a FLT3-ITD mutation experienced some form of complete remission, typically one in which the leukemia was cleared from the bone marrow, but the patient still needed blood and platelet transfusions. Thirty-four percent (13) of the 38 participants in whom the FLT3-ITD mutation was not detectable experienced this type of response.

The most common side effects with quizartinib were nausea (38 percent), anemia (29 percent), QT prolongation (an abnormality found on an EKG; 26 percent), vomiting (26 percent), febrile neutropenia (development of fever in someone with low white blood cell count; 25 percent), diarrhea (20 percent), and fatigue (20 percent). Fourteen patients (10 percent) experienced side effects severe enough to discontinue taking the drug. Investigators have been testing lower doses of the medication since the trial to reduce side effects, Levis says.

Long-term survival from the therapy is still unknown, Levis says, but of the group of 137 patients, 47 (34 percent) were able to receive a transplant after responding to quizartinib. Some of these patients have survived two years after treatment with no disease recurrence.

Based on results, the company that makes the drug, Ambit Biosciences, is planning larger Phase III trials, in which patients who have the FLT3 mutation will receive either quizartinib or chemotherapy after random grouping. Meanwhile, Levis and other physicians are continuing to study the drug in a clinical trial testing lower doses.


Contact: Vanessa Wasta
Johns Hopkins Medicine

Related medicine news :

1. Streetcar tracks blamed in one-third of Toronto bike accidents
2. Third of Hospital Staff Say Hand-Washing Reminders Unwelcome
3. Healthy lifestyle reduces the risk of hypertension by two thirds
4. Two-Thirds of U.S. Youth Have Had Oral Sex, CDC Reports
5. Surgical patient safety program lowers SSIs by one-third following colorectal operations
6. More Than a Third of Births Unintended: CDC
7. Two-Thirds of Osteo Hip Fractures Occur After 80: U.S. Study
8. One-Third of U.S. Homeless Population Is Obese: Study
9. One-third of adult Americans with arthritis battle anxiety or depression
10. High-risk carotid artery plaque formation is increased in older COPD patients
11. Restricting high-risk individuals from owning guns saves lives
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... The ... this summer, ushering in a new era of publicly accessible automated technology. Now, ... will continue to offer guests an up-close look at the shuttle at MOSI’s ...
(Date:11/30/2015)... ... 2015 , ... On Saturday, October 24th, 2015, at the Mill Race Park ... a 5K walk known as “Making Strides Against Breast Cancer”. Patients and staff members ... located in Battle Creek, joined in for this campaign that sought to raise donations ...
(Date:11/30/2015)... ... 30, 2015 , ... During the week of Thanksgiving, the ... for its research, education, support, and advocacy efforts. The campaign is held every ... Mesothelioma Applied Research Foundation, which also goes by Meso Foundation, holds the ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to Los Angeles bariatric surgeon Michael ... not necessarily caused by real hunger, but instead by a hormone called ghrelin ... that, while many patients are aware that weight loss surgery can help patients lose ...
(Date:11/30/2015)... ... 30, 2015 , ... A record crowd gathered at the Pennsylvania Biotech Center ... Baruch S. Blumberg Institute. , The institute, which is the research arm of the ... leaders for the conference, which focused on ways companies can work to reduce the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
(Date:11/30/2015)... Nov. 30, 2015 NHS Supply Chain ... TrueBeam™ machines from Varian Medical Systems (NYSE: ... to replace older machines and institute modern radiotherapy ... public hospitals. The order, placed in September, also ... for Varian,s RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... N.J. , Nov. 30, 2015  Novartis will ... at the 57 th American Society of Hematology ... lymphomas and myelomas as well as supportive care, including ... addition to personalized cell therapies. The ASH Annual Meeting ... Florida . Novartis Oncology . "We ...
Breaking Medicine Technology: